These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 2533146)
21. Hormones and pathogenesis of uterine fibroids. Reis FM; Bloise E; Ortiga-Carvalho TM Best Pract Res Clin Obstet Gynaecol; 2016 Jul; 34():13-24. PubMed ID: 26725037 [TBL] [Abstract][Full Text] [Related]
22. Treatment effects of GnRH agonist on the binding of estrogen and progesterone, and the histological findings of uterine leiomyomas. Uemura T; Mori J; Yoshimura Y; Minaguchi H Asia Oceania J Obstet Gynaecol; 1991 Dec; 17(4):315-20. PubMed ID: 1724899 [TBL] [Abstract][Full Text] [Related]
23. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256 [TBL] [Abstract][Full Text] [Related]
24. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase. Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092 [TBL] [Abstract][Full Text] [Related]
26. Effects of gonadotrophin-releasing hormone agonist on uterine fibroids and bone density. Bianchi G; Costantini S; Anserini P; Rovetta G; Monteforte P; Menada MV; Fagà L; De Cecco L Maturitas; 1989 Sep; 11(3):179-85. PubMed ID: 2512467 [TBL] [Abstract][Full Text] [Related]
27. [Interaction of tamoxifen with cytosol estradiol receptors in myoma and histologically unchanged myometrium]. Kareva EN; Kostyleva OI Biull Eksp Biol Med; 1993 Mar; 115(3):264-5. PubMed ID: 8054615 [TBL] [Abstract][Full Text] [Related]
28. The management of leiomyoma uteri by GnRH analogues. Giorgino FL; Cetera C Clin Exp Obstet Gynecol; 1991; 18(2):137-43. PubMed ID: 1833095 [TBL] [Abstract][Full Text] [Related]
29. Treatment of peri-menopausal women: potential long-term therapy with a depot GnRH agonist combined with hormonal replacement therapy. Maheux R; Lemay A Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():13-7. PubMed ID: 1532506 [No Abstract] [Full Text] [Related]
30. Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist. Donnez J; Dolmans MM Fertil Steril; 2020 Oct; 114(4):739-741. PubMed ID: 32854931 [No Abstract] [Full Text] [Related]
31. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Matta WH; Shaw RW; Nye M Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020 [TBL] [Abstract][Full Text] [Related]
33. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group. Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863 [TBL] [Abstract][Full Text] [Related]
34. Pelvic pain complicating LHRH analogue treatment of fibroids. Chipato T; Healy DL; Vollenhoven B; Buckler HM Aust N Z J Obstet Gynaecol; 1991 Nov; 31(4):383-4. PubMed ID: 1799362 [TBL] [Abstract][Full Text] [Related]
35. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151 [TBL] [Abstract][Full Text] [Related]
36. Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases. Lemay A Fertil Steril; 1987 Jul; 48(1):10-2. PubMed ID: 2954859 [No Abstract] [Full Text] [Related]
37. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist. Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349 [TBL] [Abstract][Full Text] [Related]
38. [Pathogenesis and conservative therapy of uterine leiomyoma]. Mori T; Fujii S; Konishi I Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul; 38(7):1144-9. PubMed ID: 3091738 [No Abstract] [Full Text] [Related]